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The carboxyl-terminal domain (CTD) of the largest subunit of RNA polymerase II (RNAP II) ordinarily exists in electrophoretically
distinct hypophosphorylated and hyperphosphorylated forms. Human cytomegalovirus infection induced forms of this subunit whose
electrophoretic mobilities were intermediate without decreases in abundance of the original forms. Phosphatase treatment nearly eliminated
the intermediate migrating forms. In vitro, the viral protein kinase, UL97, phosphorylated this subunit, a recombinant protein containing the
CTD, and peptides containing the CTD consensus sequence, YSPTSPS. Phosphorylation occurred predominantly on serine 5 and was
substantially reduced when either serine 2 or 5 was already phosphorylated. The abundance of the intermediate and hypophosphorylated
forms was reduced at most twofold during infections in which UL97 was genetically or pharmacologically inhibited. These results identify a
new pattern of RNA polymerase II modification induced by virus infection and a viral enzyme that phosphorylates the CTD in vitro, but only
possibly in vivo.
D 2004 Elsevier Inc. All rights reserved.Keywords: Phosphorylation; Cytomegalovirus; ProteinIntroduction
RNA polymerase II (RNAP II) is the enzyme that tran-
scribes protein-coding genes in eukaryotic cells. The largest
subunit of RNAP II includes a carboxyl-terminal domain
(CTD), which lies next to the exit groove for nascent
transcripts (Cramer et al., 2001). The CTD consists of
highly conserved heptapeptide repeats (consensus sequence,
YSPTSPS), the number of which varies among organisms
(Allison et al., 1988). During the initiation and elongation
phases of transcription, the CTD cycles through various0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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Canada H7V 1B7.phosphorylation states of which the major two forms
(RNAP IIA and IIO) can be distinguished by electrophoretic
mobility (reviewed in Hirose and Manley, 2000; Kobor and
Greenblatt, 2002; Maniatis and Reed, 2002; Oelgeschla¨ger,
2002; Palancade and Bensaude, 2003). In particular, RNAP
II whose CTD is hypophosphorylated (RNAP IIA) is
preferentially recruited to preinitiation complexes at a pro-
moter. Then, during initiation and elongation, the CTD
becomes highly phosphorylated, resulting in the hyperphos-
phorylated form, RNAP IIO. CTD phosphorylation is con-
trolled by several cellular kinases. Some of these, such as
the kinase component of transcription elongation factor P-
TEFb (CDK9/cyclin T1), have been reported to phosphor-
ylate the serines at either or both the second and fifth
positions (Ser-2 and Ser-5) in the consensus sequence,
although others, such as the kinase component of the
general transcription initiation factor (TF) IIH (CDK7/cyclin
H), mainly phosphorylate Ser-5 (Kim et al., 2002; Ram-
anathan et al., 2001; Zhou et al., 2000). These specific
phosphorylation events mediate different transcriptional
activities of the CTD and couple transcription to posttran-
Fig. 1. HCMV infection induces alterations in RNAP II. Immunoblot
analysis of RNAP II large subunit from mock-infected HFF cells (M),
harvested at 12 h p.i., or HFF cells infected with wt HCMVand harvested at
selected time points in h p.i. (indicated at the top). The top panel shows an
immunoblot probed with ARNA3a, which recognizes RNAP II large
subunit regardless of phosphorylation state and the bottom panel shows the
blot probed with 8WG16, which does not recognize the hyperphosphory-
lated form (IIO), but recognizes less phosphorylated forms (hypophos-
phorylated, IIA, and intermediate forms, IIi). The positions of the various
forms is indicated to the right.
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adenylation. Thus, changes in CTD phosphorylation are of
considerable interest.
Many viruses induce alterations in host cell gene expres-
sion. These alterations include changes in the transcriptional
machinery such as modification of the CTD (reviewed in
Knipe et al., 2001). One well-studied example is the
recruitment of CDK9/cyclin T1 by the human immunode-
ficiency virus (HIV) Tat protein, which results in hyper-
phosphorylation of the CTD and stimulation of elongation
of HIV transcripts (reviewed in Taube et al., 1999). A
second example occurs during herpes simplex virus (HSV)
infection. Early during the course of viral infection, the
phosphorylation state of the largest subunit of RNAP II is
altered, such that the IIO and IIA forms are depleted and
replaced with alternately phosphorylated forms of interme-
diate electrophoretic mobility (Rice et al., 1994). These new
forms of RNAP II collectively are referred to as RNAP IIi
(intermediate or infected cell form). The HSV protein kinase
UL13 and viral immediate early protein ICP22 are each
required for the efficient formation of RNAP IIi, for the
efficient depletion of the IIA form, and for the efficient
expression of certain viral genes (Long et al., 1999; Purves
et al., 1993). However, it has not been shown that the UL13
protein kinase phosphorylates RNAP II or its CTD, and
indeed, the possibility that the effect on RNAP II (e.g., via
effects on ICP22 or cell kinases), is indirect has been
entertained (Long et al., 1999).
Like HSV, human cytomegalovirus (HCMV) is a her-
pesvirus. The HCMV homolog of HSV UL13 is UL97
(Chee et al., 1989). Both proteins are members of the HvUL
protein kinase family (McGeoch et al., 1995). UL97 is
perhaps the most atypical member of this family. UL97
has been heterologously expressed, purified, and character-
ized (Baek et al., 2002a, 2002b; He et al., 1997). It is a
serine/threonine protein kinase with several unusual prop-
erties including a high pH optimum, resistance to high salt
concentrations, and an uncommon preference for peptide
substrates with basic residues at the P + 5 position (Baek et
al., 2002b; He et al., 1997). It also has the ability to
phosphorylate certain nucleoside analogs such as ganciclo-
vir, which is important for their antiviral activities (Littler et
al., 1992; Sullivan et al., 1992; Talarico et al., 1999). UL97
is critical for viral replication (Krosky et al., 2003b; Prichard
et al., 1999; Wolf et al., 2001). In contrast, HSV UL13 is
less critical for viral replication (Long et al., 1999; Overton
et al., 1994; Purves et al., 1993) and lacks the ability to
phosphorylate nucleoside analogs (Ng et al., 1996). Inter-
estingly, the modest replication defect of an HSV UL13
mutant can be repaired by HCMV UL97 (Ng et al., 1996).
This raised the possibility that HCMV infection or UL97
might modify RNAP II.
To investigate this possibility, we studied the effects of
infection by wild-type HCMVon the electrophoretic mobil-
ity of the largest subunit of RNAP II. We found that HCMV
infection induced the formation of RNAP IIi, but withoutdepletion of the IIA or IIO. This led us to investigate the
phosphorylation of RNAP II and its CTD in vitro by UL97,
and the importance of UL97 for modification of RNAP II in
cells.Results
Modification of RNAP II during HCMV infection
During HSV infection, the abundance of hypo- and
hyperphosphorylated forms of the largest subunits of RNA
polymerase II (RNAP IIA and RNAP IIO, respectively)
declines and the abundance of intermediately migrating
forms (RNAP IIi) increases (Rice et al., 1994). To investi-
gate phosphorylated forms of RNAP II during HCMV
infection, lysates from mock-infected cells or cells infected
for various times with wt HCMV were analyzed by immu-
noblotting using two different monoclonal antibodies direct-
ed against the largest subunit of RNAP II. The monoclonal
antibody, ARNA 3a, recognizes both IIA and IIO, while the
monoclonal antibody 8WG16, whose binding is blocked by
phosphorylation of Ser-2, recognizes the hypophosphory-
lated form, IIA, but not the hyperphosphorylated form, IIO
(Cho et al., 2001; Patturajan et al., 1998). Both antibodies
recognize the HSV-induced IIi forms (Rice et al., 1994).
Within 24 h p.i. by HCMV, both RNAP IIO (Fig. 1, top
panel) and IIA (Fig. 1, top and bottom panels) accumulated
above the levels seen in uninfected cells. This increase
continued through 72 h p.i. During the same time period,
there was little change in the amount of RNAP II in mock-
infected cells (data not shown). In addition, in HCMV-
infected cells, there was a progressive appearance of inter-
mediate migrating forms, beginning about 24 h p.i. and
becoming especially evident from 60 h through 72 h, where
there abundance increased more than did the IIA and IIO
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similarity to the forms observed during HSV infection (Rice
et al., 1994). To determine if the altered electrophoretic
mobilities of the RNAP IIi species are due to phosphoryla-
tion, we treated lysates with lambda phosphatase before
analysis by immunoblotting (Fig. 2). Whether detected with
antibody ARNA 3a (top panel) or 8WG16 (bottom panel),
the RNAP IIi species nearly disappeared following phos-
phatase treatment (lane 3), leaving the IIA species as the
only abundant RNAP II form. Mock incubation had little or
no effect (lane 2). Thus, the formation of intermediately
phosphorylated forms of RNAP II (RNAP IIi) appears to be
similar between HSV and HCMV; however, unlike the case
during HSV infection, forms IIA and IIO are not depleted,
but rather accumulate.
Modification of the largest subunit of RNAP II, GST-CTD,
and CTD peptide by UL97 in vitro
The alterations in RNAP II that we observed in HCMV-
infected cells increased our interest in the possibility that
UL97 could directly phosphorylate RNAP II on its CTD. To
investigate this possibility, we initially assayed whetherFig. 2. Phosphatase-sensitivity of RNAP IIi. HFF cells infected with wt
HCMV were harvested at 72 h p.i. Lysates were prepared and dialyzed
against lambda phosphatase buffer as described in Materials and methods
and then either incubated for 30 min alone, either on ice (lane 1) or at 30 jC
(lane 2), or with lambda phosphatase (lane 3). The top panel shows an
immunoblot probed with ARNA3a, which recognizes RNAP II large
subunit regardless of phosphorylation state, and the bottom panel shows an
immunoblot probed with 8WG16, which does not recognized the hyper-
phosphorylated form (IIO). The positions of the different RNAP II species
are indicated to the right of each panel and the position of a prestained
molecular weight marker (BioRad) is indicated to the left of each panel.
Fig. 3. Phosphorylation of RNAP II, GST-CTD, and CTD peptide by UL97.
(A) Yeast RNAP II (150 ng) was phosphorylated by yeast TFIIH (lanes 1
and 2), GST-UL97 (lanes 3 and 4), or the K355Q GST-UL97 mutant protein
(lane 6), either in the absence (lanes 2 and 4–6) or presence (lanes 1 and 3)
of 3 AM maribavir. The position of the largest subunit of RNAP II
following SDS-PAGE and autoradiography (upper panel) or Coomassie
staining (bottom panel) is indicated by arrows. (B) GST-CTD (200 ng),
containing 26 repeats of the conserved heptapeptide, was either incubated
alone (lane 1), with yeast TFIIH (lanes 3 and 4), with GST-UL97 (lanes 5
and 6), or the K355Q GST-UL97 mutant protein (lane 7), in kinase buffer
with radiolabeled ATP either in the absence (lanes 1, 3, 5, and 7) or
presence (lanes 4 and 6) of 3 AM maribavir. GST-UL97 incubated alone in
kinase buffer with radiolabeled ATP is shown in lane 2. The positions of
GST-UL97 and GST-CTD following SDS-PAGE and autoradiography are
indicated. (C) Synthetic CTD peptide (10 Ag) was incubated alone (lane 5),
with GST-UL97 (lanes 2 and 3), or the K355Q GST-UL97 mutant protein
(lane 4) in kinase buffer with radiolabeled ATP either in the absence (lane
2) or presence (lane 3) of 3 AM maribavir. GST-UL97 incubated alone in
kinase buffer with radiolabeled ATP is shown in lane 1. The positions of
GST-UL97 and CTD peptide following SDS-PAGE and autoradiography
are indicated.
Fig. 4. Phosphoamino acid and sequence analysis. (A) GST-CTD and
synthetic CTD peptide were phosphorylated by GST-UL97, gel purified,
hydrolyzed, and subjected to thin-layer electrophoresis with phosphoserine
(P-Ser), phosphothreonine (P-Thr), and phosphotyrosine (P-Tyr) standards.
The positions of the phosphoamino acid standards (as indicated between the
panels) were visualized with ninhydrin staining, and the position of the
radiolabeled peptide visualized by autoradiography. (B) Sequence analysis.
Synthetic CTD peptide, phosphorylated by GST-UL97, was subjected to
automated sequencing. The material in each fraction was subjected to
automated peptide sequencing. The material released at each cycle was split
to identify the amino acid by RP-HPLC (shown at the bottom of each panel)
and the radioactivity by scintillation counting (indicated by black bars). The
major residues phosphorylated are underlined.
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phosphorylated by purified recombinant GST-UL97. Re-
combinant, purified yeast TFIIH (Cho et al., 1997) was used
as a positive control. The largest subunit of RNAP II was
phosphorylated by both TFIIH and UL97 (Fig. 3A, lanes 2
and 4). To test for the specificity of phosphorylation by
UL97, we employed a specific UL97 inhibitor, maribavir
(Baek et al., 2002b; Biron et al., 2002), and a catalytically
inactive point mutant of UL97, K355Q (He et al., 1997).
Phosphorylation by UL97, but not TFIIH, was abolished by
maribavir (lanes 1 and 3). No phosphorylation was observed
in the absence of added kinase (lane 5) or using the K355Q
mutant (lane 6). Similar amounts of RNAP II were present
in each lane, as verified by Coomassie staining of the gel
(Fig. 2A, bottom panel).
Phosphorylation of the largest subunit of RNAP II by
TFIIH and other enzymes occurs on the CTD, which
consists of heptapeptide consensus repeats of YSPTSPS
(Feaver et al., 1991; Lu et al., 1992; Serizawa et al.,
1993). Recombinant GST-CTD, consisting of 26 consensus
heptads, was tested as a substrate for UL97 and TFIIH and
was phosphorylated by both (Fig. 3B, lanes 3 and 5). As
before, phosphorylation of CTD (and autophosphorylation)
by UL97 (lane 6), but not TFIIH (lane 4), was essentially
eliminated by maribavir. No phosphorylation was observed
in the absence of added kinase (lane 1) or using the K355Q
mutant (lane 7).
To determine if the CTD itself was sufficient to serve as a
substrate for UL97, a synthetic peptide consisting of three
repeats of the consensus heptapeptide was tested as a
substrate. It was phosphorylated extensively by UL97
(Fig. 3C, lane 2). Phosphorylation was eliminated by
maribavir, and the K355Q UL97 mutant did not detectably
phosphorylate the peptide. We conclude that UL97 can
phosphorylate the RNAP II CTD in vitro.
UL97 phosphorylates CTD predominantly on Ser-5
Each CTD heptapeptide can potentially be phosphory-
lated on three different serines, a threonine, and a tyrosine.
To determine which amino acid is phosphorylated by UL97,
GST-CTD (26 repeats) and the CTD peptide (3 repeats)
were each phosphorylated by UL97 using 32P-ATP and
hydrolyzed with hydrochloric acid. The resulting amino
acids were separated electrophoretically, and autoradiogra-
phy revealed that phosphorylation had occurred nearly
exclusively on serine residues (Fig. 4A). In order to identify
the specific serine residue(s) phosphorylated, N-terminal
sequencing of 32P labeled CTD peptide was performed.
Each cycle of sequencing was monitored for the release of
radioactivity, and it was found predominantly in cycles
corresponding to Ser-5 of the first and second repeat units
(Fig. 4B). (Radioactivity in the cycle corresponding to Pro-6
is most likely due to carryover.) Ser-2 of the second repeat
and third repeat was also phosphorylated, but to a lesser
degree.Prior phosphorylation of Ser-2 or Ser-5 blocks CTD
phosphorylation by UL97
We also investigated the ability of synthetically phos-
phorylated CTD peptides (in this case, containing four
heptad repeats) to serve as substrates for UL97 in vitro.
Peptides in which Ser 2 or Ser 5 were synthetically
phosphorylated were only very weakly phosphorylated by
UL97, with extents of phosphorylation being only 15% and
8% of the unphosphorylated peptide (compare lanes 2 and 3
to lane 1 in Fig. 5), and a peptide in which both Ser 2 and
Ser 5 were prephosphorylated was not detectably phosphor-
ylated by UL97 (lane 4). Thus, prior phosphorylation of Ser-
5 does not result in compensatory utilization of other sites.
Moreover, the ability of UL97 to phosphorylate its major
Fig. 6. Induction of RNAP IIi and IIA following genetic or pharmacological
inhibition of UL97. Immunoblot analysis of RNAP II large subunit from
HFF cells that were mock infected (M) or infected with wt HCMV strain
AD169 (A) or RCD97 (R), in which UL97 is deleted, or with wt in the
presence of 1 AM of the drug, maribavir (D) for 72 h. The top panel shows
an immunoblot probed with ARNA3a that recognizes RNAP II large
subunit regardless of phosphorylation state, the middle panel shows the blot
probed with 8WG16, which does not recognize the hyperphosphorylated
form (IIO), but recognizes less phosphorylated forms (hypophosphorylated,
IIA, and intermediate forms, IIi), and the bottom panel with an antibody
that recognizes clathrin. The positions of the various polypeptides are
indicated to the right of the panels. All lanes contain extracts from the same
number of cells.
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Ser-2 being unphosphorylated.
Genetic or pharmacological inhibition of UL97 at most
modestly affects accumulation of IIi and IIA
Given the ability of UL97 to phosphorylate the CTD in
vitro, we then compared the effects of infection of an
HCMV UL97 null mutant virus (RCD97) with those of wt
HCMV on the accumulation of the various forms of RNAP
II. As illustrated in Fig. 6, reduced amounts of RNAP IIi
and IIA were observed in mutant-infected cells compared
with wt-infected cells, whether detected by the ARNA 3a or
the 8WG16 antibody. This effect was rather modest com-
pared with the overall increase in RNAP II in virus-infected
cells versus mock-infected cells (about twofold less than
that of wt based on a dilution series of lysates from wt-
infected cells), but reproducible. These differences between
mutant and wt were not due to differences in preparation or
analysis of the proteins, as similar amounts of RNAP IIO
and clathrin (a polypeptide of similar size) were observed
on the same immunoblots (Fig. 6). (The amounts of these
latter polypeptides were within the linear range of the
assay.)
We also investigated the effect of maribavir on accumu-
lation of various forms of RNAP II. In the experiment
shown in Fig. 6, maribavir treatment of wt-infected cells
resulted in a very slight decrease (<twofold) in accumulation
of RNAP IIi and IIA relative to untreated wt-infected cells.Fig. 5. Prior phosphorylation of CTD peptides blocks further phosphory-
lation by UL97. Synthetic CTD peptides either lacking phosphorylated
serine residues (lane 1) or with phosphate groups on serine residues at
positions 2 (lane 2), 5 (lane 3), or both 2 and 5 (lane 4) were incubated with
GST-UL97 in kinase buffer with radiolabeled ATP. The positions of GST-
UL97 and CTD peptide following SDS-PAGE and autoradiography are
indicated in the top panel and the names and sequences of the peptides are
indicated below.However, in two other experiments, no difference was
observed. Thus, the absence or inhibition of UL97 had, at
most, a twofold effect on the accumulation of RNAP IIi and
IIA induced by HCMV.Discussion
Our results show that wt HCMV infection induces a new
pattern of RNAP II modification—the accumulation of
intermediately migrating forms of RNAP II without deple-
tion of the hypophosphorylated and hyperphosphorylated
forms ordinarily found in uninfected cells. These observa-
tions encouraged us to perform studies that showed that
UL97 can phosphorylate RNAP II CTD in vitro, predom-
inantly on Ser-5, but with a requirement for unphosphory-
lated Ser-2 residues. To our knowledge, this is the first
report of a virally encoded protein kinase that can phos-
phorylate RNAP II CTD in vitro. This led us to test the
hypothesis that UL97 is necessary for the pattern of RNAP
II modification in infected cells. We found that this enzyme
is not necessary although it might contribute. We discuss
these findings below.
HCMV induces a new pattern of RNAP II modification
The pattern of RNAP II phosphorylation induced by
HCMV both differs from and resembles those induced by
other viruses. Unlike what we have observed with HCMV,
HIV has not been reported to induce global changes in
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activate CDK9/Cyclin T1 to transcription units containing
trans-activation response elements, resulting in hyperphos-
phorylation of the CTD (reviewed in Taube et al., 1999).
Thus, this mechanism is promoter-specific. Like HCMV,
HSV induces global changes in RNAP II phosphorylation
that involve the formation of intermediate-migrating forms
(RNAP IIi). However, unlike the accumulation of both
standard forms of RNAP II (IIA and IIO) that occurs during
HCMV infection, HSV induces their depletion (Rice et al.,
1994). The depletion of RNAP IIO has been correlated with
repression of host cell transcription by HSV (Spencer et al.,
1997). Consistent with this correlation, HCMV infection
both induces RNAP IIO accumulation (this report) and host
cell transcription (reviewed in Mocarski and Courcelle,
2001); this induction may also help explain the increases
in amounts of RNAP IIA and O, and also clathrin (Figs. 1
and 6) during HCMV infection. It has been suggested that
the depletion of RNAP IIO induced by HSV is due to a
dissociation of TFIIE from RNAP II holoenzyme, because
TFIIE stimulates CTD phosphorylation by TFIIH (Jenkins
and Spencer, 2001). In this view, the formation of RNAP IIi
could result in part from partial phosphorylation of CTD by
TFIIH, as has been observed in vitro when TFIIH is
stimulated by certain TFIIE mutants (Okamoto et al.,
1998). The accumulation of RNAP IIO in HCMV-infected
cells tends to argue against TFIIE dissociation alone
explaining the formation of RNAP IIi in these cells. Re-
gardless, the novel pattern of RNAP II modification that we
have observed is likely to be important for gene expression
in HCMV-infected cells.
Phosphorylation of CTD by UL97 in vitro
Our conclusion that UL97 can phosphorylate RNAP II
and, specifically, its CTD in vitro rests on two important
controls for specificity that ensure that phosphorylation is
not due to other contaminating kinases: (1) The lack of
activity of the catalytically inactive K355Q mutant protein
that was purified in identical fashion and (2) sensitivity to
the specific UL97 inhibitor, maribavir. The RNAP II CTD
thus joins a small, but growing list of exogenous protein and
peptide substrates that UL97 can phosphorylate in vitro
(Baek et al., 2002a, 2002b; Krosky et al., 2003a).
It is interesting to compare UL97 with CTD kinases that
have been implicated in regulation of gene expression. As
has been reported for the CDK7/cyclin H component of
TFIIH (Gebara et al., 1997; Ramanathan et al., 2001; Roy et
al., 1994; Trigon et al., 1998; Zhou et al., 2000), UL97
exhibits a preference for Ser-5 of the heptapeptide consen-
sus sequence. UL97 can also phosphorylate Ser-2, albeit to a
lesser extent. Ser-2 phosphorylation has been reported for
the CDK9/cyclin T1 of P-TEFb, although there is disagree-
ment in the literature regarding its extent (Kim et al., 2002;
Ramanathan et al., 2001; Zhou et al., 2000). It is worth
emphasizing that we analyzed the sites of phosphorylationdirectly, by sequencing phosphorylated CTD peptides, pro-
viding a quantitative assessment of their extents of phos-
phorylation. In contrast, most studies of TFIIH and P-TEFb
kinases have used more indirect methods such as assessing
the effects of substitutions at Ser-2 or Ser-5, or of antibodies
that recognize phosphorylated Ser-2 or Ser-5. The specific-
ity of such antibodies can be limited (Palancade and
Bensaude, 2003). As observed with the TFIIH kinase, but
not the P-TEFb kinase (Ramanathan et al., 2001), CTD
peptides containing phosphorylated Ser-2 are poor sub-
strates for UL97, despite the predominant phosphorylation
of Ser-5. Interestingly, these three kinases are all inhibited
by benzimidazole ribonucleosides-5,6, dichloro-h-D-ribo-
sylbenzimidazole (DRB) CDK7/cyclin H and CDK9/cyclin
T1 (Marshall et al., 1996; Yankulov et al., 1995), and
maribavir in the case of UL97 (Baek et al., 2002b; Biron
et al., 2002). DRB and maribavir differ only in substituents
at the 2-position of the heterocycle and in the stereochem-
istry of the glycosidic bond.
The CTD and CTD peptides differ from other substrates
robustly phosphorylated by UL97 in that they lack a basic
residue at the P + 5 position. We do not know what features
of the CTD sequence account for its utilization by UL97.
Previous results had indicated that unlike many kinases
(Songyang et al., 1996), the P-3 residue had little impor-
tance for UL97 activity (Baek et al., 2002a, 2002b). Ser-2 is
at the P-3 position relative to the predominant site of
phosphorylation, Ser-5. This result suggests a negative
effect of a phosphate at that position or at the P + 4 position.
Alternatively, the phosphorylated peptide might be ‘‘seen’’
by the enzyme as a product, and is not phosphorylated.
Does UL97 contribute to CTD phosphorylation in infected
cells?
Given that the UL97 null mutant still induced the
formation of RNAP IIi and increased amounts of RNAP
IIA relative to mock-infected cells, clearly UL97 plays at
most a modest role in modification of RNAP II in HCMV-
infected cells. The minimal effects of maribavir on forma-
tion of RNAP IIi suggest an even less important role. (The
differences in RNAP II modification observed between
mutant-infected vs. drug-treated, wt-infected cells could be
due to several factors including greater penetrance of the
mutant vs. the drug.) It is possible that UL97 does phos-
phorylate the CTD in infected HFF cells, but given the
limited effects overall on RNAP II modification, this will be
difficult to investigate further. It is also possible that UL97
might have a larger role in specific cell types, or, of course,
that UL97 does not directly phosphorylate the CTD in any
infected cells. In any event, inasmuch as UL97 is the only
well-established HCMV-encoded protein kinase and as there
is no evidence for a HCMV-encoded phosphatase, appar-
ently the altered pattern of RNAP II modifications in
HCMV-infected cells does not require a virus-encoded
kinase or phosphatase.
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similar, at least qualitatively, to what is observed following
infection by an HSV mutant deficient in the UL13 protein
kinase. Infection with either an HCMV UL97 mutant (this
report) or an HSV UL13 mutant (Long et al., 1999) reduced,
but did not abolish, accumulation of RNAP IIi without
affecting the amount of RNAP IIO. However, with respect
to RNAP IIA, opposite effects were observed: Infection with
the HCMV UL97 mutant resulted in reduced formation of
RNAP IIA, although infection with the HSV UL13 mutant
resulted in more RNAP IIA than did infection with wt HSV.
This latter observation led to the suggestion that at least some
RNAP IIA is converted to RNAP IIi in HSV-infected cells,
possibly by UL13 (Long et al., 1999). The simplest inter-
pretation of our data is that UL97 does not convert RNAP
IIA to IIi. To explain why there is reduced formation of
RNAP IIA in UL97 mutant-infected cells, a more compli-
cated interpretation starts with the assumption that UL97
directly does phosphorylate RNAP II in HCMV-infected
cells. If so, as prior phosphorylation of CTD peptides on
either Ser-2 or Ser-5 precludes further phosphorylation,
UL97 would be expected to phosphorylate IIA relatively
lightly, resulting not only in IIi species but also in even less
phosphorylated forms that comigrate with IIA. Thus, both IIi
and IIA would appear to be diminished in the absence of
UL97. However, this pattern could be due to indirect effects.
UL97 is very important for productive infection by
HCMV, but its role is controversial. Studies of maribavir
(Biron et al., 2002), RCD97 (Wolf et al., 2001), or both
(Krosky et al., 2003b) have indicated that UL97 is most
important for DNA synthesis, capsid assembly, or nuclear
egress, respectively. Additionally, UL97 has been shown to
phosphorylate the viral polymerase accessory protein,
UL44, in vitro and to be essential for its normal phosphor-
ylation in infected cells (Krosky et al., 2003a). Regardless of
these findings and the only modest role of UL97 in RNAP II
modification, the similarities of UL97 to two cellular
kinases involved in transcriptional elongation, and to HSV
UL13, continue to provoke the speculation that UL97 plays
a role in gene expression. Although UL97 is not required for
the efficient expression of certain viral genes in HFF cells
(Krosky et al., 2003b; Prichard et al., 1999; Wolf et al.,
2001), it could conceivably enhance the expression of other
viral genes, host genes, or both, which might in turn
enhance virus replication, in these or other cells. Further
studies of the effects of UL97 mutations on host and viral
gene expression may be warranted.Materials and methods
Reagents
Maribavir [5,6-dichloro-2-(isopropylamino)-1-h-L-ribo-
furanosyl-1H-benzimidazole; also known as 1263W94], a
specific inhibitor of UL97 (Baek et al., 2002b; Biron et al.,2002), was synthesized and kindly provided by GlaxoS-
mithKline. Unless otherwise noted, all other chemicals were
purchased from Sigma.
Cells and viruses
Human foreskin fibroblast cells (HFFs) were obtained
from American Type Culture Collection (ATCC) and main-
tained in Dulbecco’s modification of Eagle’s medium
(DMEM, Clontech) with 10% fetal bovine serum (FBS;
Atlanta Biologicals). Cells were subcultured every 2–3 days
and screened monthly for mycoplasma contamination by
PCR. HCMV wild type (wt) was also obtained from ATCC.
The UL97 null mutant virus (RCD97), which contains an
insertion encoding the E. coli lacZ and gpt genes that
replaces most of the UL97 open reading frame (Prichard
et al., 1999), was provided generously by Mark Prichard.
Viral stocks were prepared and titered as previously de-
scribed (Turk et al., 1987).
Spodoptera frugiperda 9 (Sf9) cells, obtained from
ATCC, were maintained in Grace’s insect medium (Life
Technologies), supplemented with 10% FBS, 100 U/ml
penicillin, and 100 Ag/ml streptomycin B. Recombinant
baculoviruses expressing wild-type or mutant K355Q glu-
tathione-S-transferase (GST)–UL97 fusion proteins (He et
al., 1997) were propagated and maintained on Sf9 cells by
standard methods (Crossen and Gruenwald, 1998).
Western blot analysis
HFF cells were seeded in 6-well tissue culture plates and
incubated overnight at 37 jC. Cells were infected at a
multiplicity of one plaque forming unit per cell in DMEM
with 5% FBS for 2 h (inocula titers were checked by back
titration). Inocula were removed and the cells were washed
2 times with DMEM with 5% FBS. DMEM and 5% FBS,
with or without 1 AM maribavir, was then added and
incubation at 37 jC continued for the indicated times
post-infection (p.i.). At selected times, the cells were
washed with phosphate-buffered saline (PBS) and either
immediately lysed in SDS-PAGE loading buffer, or har-
vested with 0.05% trypsin and 0.5 mM EDTA in PBS,
collected by centrifugation (5 min at 1000g at 4 jC), and
lysed in SDS-PAGE loading buffer. In some experiments,
Phosphatase Inhibitor Cocktails 1 and 2 were included
during lysis. The same results were obtained with or without
these inhibitors.
For studies of the phosphatase sensitivity of RNAP IIi
species, cells were lysed in 50 mM Tris–HCl, pH 7.9, 500
mM NaCl, 1% Triton-X-100, 0.5% sodium deoxycholate,
0.1% SDS and Complete Protease Inhibitor cocktail (Roche).
Lysates were cleared by microcentrifugation at 18000  g
for 30 min at 4 jC and dialyzed against lambda phosphatase
buffer (50 mM Tris–HCl, pH 7.9, 0.1 mM EDTA, 5 mM
DTT) supplemented with Complete Protease Inhibitor cock-
tail. Fifteen microliters of dialyzed lysate was either incu-
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units of lambda protein phosphatase (New England Biolabs).
Proteins in lysates were separated through 6% SDS-
PAGE, and the proteins were transferred to nitrocellulose
at 100 V for 3 h. The following antibodies were used for
immunoblot analysis: 8WG16 (Thompson et al., 1990),
kindly provided by Charlotte Spencer or purchased from
Biodesign International (diluted 1:1000–10000); ARNA
3a (Kramer et al., 1980) from Research Diagnostics, Inc
(1:1000); horse radish peroxidase (HRP)-conjugated sheep
anti-mouse from Amersham (1:25000–50000); anti-cla-
thrin HC from Santa Cruz Biotechnologies, Inc.,
(1:15000); HRP-conjugated donkey anti-goat from Santa
Cruz (1:50000). Membranes were blocked with Super
Block (Pierce) or with 5% nonfat dry milk (BioRad)
dissolved in Tris-buffered saline containing 0.1% Tween
20, developed with SuperSignalWest Femto substrate
(Pierce), and stripped with Restore (Pierce) or with a
solution of 62.5 mM Tris HCl, pH 6.8, 2% SDS, and 100
mM hmercaptoethanol, before reprobing. All products
were used as described in the package insert, except that
membranes were blocked overnight at 4 jC. Dilutions of
extracts were analyzed to ensure that detection signals were
within the linear ranges of the assays.
Purification of baculovirus-expressed GST-UL97 and E.
coli-expressed GST-CTD
Baculovirus-expressed GST-UL97 and GST-UL97-
K355Q were purified as detailed previously (Baek et al.,
2002a). To purify GST-CTD, overnight cultures of E. coli
(DH5a) expressing GST fused to the yeast RNAP II CTD
(Cho et al., 1997), a kind gift from E.-J. Cho and S.
Buratowski, were diluted 10-fold in fresh Luria broth
containing 100 Ag/ml ampicillin and grown for 1 h before
addition of 0.1 mM isopropyl-1-thio-h-D-galactopyranoside.
After 4 h of induction, cells were collected by centrifugation
and lysed by sonication in 20 mM Tris–HCl (pH 7.4), 0.2
M NaCl, 1 mM EDTA, 1 mM dithiothreitol, 10% glycerol,
and protease inhibitor cocktail (Roche Applied Science).
The supernatant was loaded onto a 1-ml glutathione-sephar-
ose column. The column was washed with 50 mM Tris, pH
8, 2 mM dithiothreitol, 2 mM EDTA, and 10% glycerol, and
the GST-CTD was eluted with the same buffer containing 10
mM reduced glutathione. The resulting protein was appar-
ently homogeneous based on SDS-PAGE and Coomassie
staining, and was stored at 80 jC. Protein concentrations
were determined by amino acid analysis performed by
Angelo Dickerson at the Molecular Biology Core Facility
of the Dana-Farber Cancer Institute.
Peptides
CTD peptide, which consists of three YSPTSPS repeats,
was purchased from Research Genetics. Peptides CTD4-WT
(four YSPTSPS repeats), CTD4-S2P (same as WT exceptSer-2 is phosphorylated), CTD4-S5P (same as WT except
Ser-5 is phosphorylated), and CTD4-S2P/S5P (same as WT
except Ser-2 and Ser-5 are phosphorylated) were generous
gifts from Cho et al. (2001). The sequences were verified by
laser desorption mass spectroscopy and the concentrations
of each solution were quantified by amino acid analysis by
James Lee and Angelo Dickerson, respectively, at the
Molecular Biology Core Facility of the Dana-Farber Cancer
Institute.
Protein kinase assays
In vitro phosphorylations were performed in kinase
buffer (50 mM Tris–HCl, pH 9.0, 300 mM NaCl, 10 mM
MgCl2, 2 mM dithiothreitol, and 5 AM ATP), with 5 ACi
g-32P ATP at >5000 Ci/mmol (ICN), wild type or mutant
GST-UL97 (100 ng) or yeast TFIIH (100 ng; generously
provided by E. Cho and S. Buratowski) and, as substrate,
either yeast RNAP II (150 ng; Cho et al., 1997) generously
provided by E.-J. Cho and S. Buratowski, GST-CTD (200
ng), synthetic CTD peptide (10 Ag), or one of the CTD-4
peptides (final concentration of 30 AM). The reactions were
incubated at 37 jC for 30 min and terminated by the
addition of 6 SDS sample buffer. The samples were boiled
for 3 min and were separated by 8% SDS-PAGE (yeast
RNAP II) or 10% or 12% SDS-PAGE (GST-CTD and
various CTD peptides).
Phosphoamino acid analysis
Kinase reactions were performed as described above with
GST-CTD (10 Ag) or CTD peptide (10 Ag). After 10% SDS-
PAGE, the GST-CTD was extracted as described previously
for GST-UL97 (He et al., 1997), and phosphorylated syn-
thetic CTD peptide was isolated from a 10% SDS poly-
acrylamide gel as described previously for extraction of
tryptic peptides from alkaline acrylamide gels (Baek et al.,
2002b). One-dimensional electrophoretic separation of ami-
no acids was performed subsequent to acid hydrolysis as
described previously (Baek et al., 2002b). Amino acid
standards were visualized with 0.2% ninhydrin in acetone,
and radioactivity was detected by autoradiography.
Identification of phosphorylation sites by amino acid
sequence analysis
CTD peptide that had been phosphorylated in vitro was
coupled to Immobilon-AA (Millipore) according to the
manufacturer’s instructions, and sequencing was performed
by James Lee of the Molecular Biology Core Facility, Dana-
Farber Cancer Institute, using previously described methods
(Baek et al., 2002b). An in-line split diverted a portion of
each sequencing cycle to a fraction collector to determine
32P content by liquid scintillation counting, the remaining
portion was employed for residue identification by reversed-
phase high performance liquid chromatography.
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